Compound ID | 3390
Class: Bacteriophage
Spectrum of activity: | Gram-positive & Gram-negative |
Details of activity: | Active against Staphylococcus aureus and Pseudomonas aeruginosa |
Institute where first reported: | Adaptive Phage Therapeutics |
Year first mentioned: | 2022 |
Highest developmental phase: | Phase 2 (NCT05269121) |
Development status: | Terminated |
Reason Dropped: | Withdrawn by sponsors; reason unclear |
External links: | |
Citation: |